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T
he mitogen-activated protein ki-
nases (MAPKs) are a class of 
serine/threonine kinases that fre-
quently act as fulcrums in the cellular 
response to stressful stimuli. Jiahuai Han 
discovered the p38 MAPK (1), and he’s 
spent much of his career characterizing 
members of the p38 family and the many 
roles they play in cells (2).
Han regards his work on p38 as an im-
portant facet of his career, but he says that 
his real interest is in the cellular response 
to stress, particularly infl  ammation (3, 4). 
His work has touched on many topics re-
lated to this subject over the course of his 
career, and Han has fearlessly pursued the 
answers to his questions, wherever they 
lead him. In fact, this pursuit has led him 
to many different geographical places—
from China at the start of his research ca-
reer, to his pre- and postdoctoral studies 
in the United States and Belgium (5), a 
tenured position at The Scripps Research 
Institute in La Jolla, California, and fi  nally 
a return to China. We called him at his lab 
at Xiamen University, Fujian Province, to 
talk about his many travels.
GROWING ABROAD
Where did you grow up?
In Anhui Province, in the 
middle of China. I grew 
up during the Cultural 
Revolution, and resources 
were scarce. In middle 
school and high school, 
we did not learn much. 
After high school, I spent 
a year in the countryside 
because there weren’t any 
other jobs available, so the 
government just sent people to the coun-
tryside to work on farms. Then I got lucky 
because they began to reopen the exams 
for entering university.
Did you know what you wanted to study?
Society was very politically oriented at that 
time, but the best students were expected 
to become scientists. So, I took the national 
exams and entered Peking University in 
Beijing, which is one of the best universi-
ties in China.
Honestly, when I went to college and 
chose to study biology, I didn’t really 
know anything about biology. I didn’t 
even know what molecular biology was. I 
gradually became more interested in it the 
longer I studied, but I didn’t have any 
clear plans for what I wanted to do. Once 
I reached graduate school, I discovered 
that the condition of the facilities and the 
research environment were very poor; 
they hadn’t yet been rebuilt after the Cul-
tural Revolution. I realized that if I wanted 
to do research, I would have to leave the 
country for more training.
What did you do next?
In China, I had become interested in can-
cer, and in trying to fi  nd antitumor mole-
cules. Bruce Beutler at UT Southwestern 
had isolated a protein called tumor necrosis 
factor (TNF), which I found very inter-
esting, so I wrote to him to see if I could 
join his lab. I became a visiting student 
in Bruce’s lab, but I com-
pleted my PhD in Brus-
sels, Belgium with Georges 
Huez. Then I went back to 
UT Southwestern to work 
with Bruce again, to work 
on TNF in infl  ammation. 
After a while, though, I 
decided that it was time to 
move again, so I went to 
Scripps, where I joined 
Richard Ulevitch’s lab as 
a senior postdoc.
STATES SOJOURN
How did you ﬁ  rst encounter p38?
When I was in Bruce’s lab, I studied the 
induction of TNF by infl  ammatory mol-
ecules like lipopolysaccharide (LPS). I 
focused on the transcriptional and trans-
lational regulation of TNF. When I got to 
Richard’s lab, I wanted to look further 
upstream, to ask what signaling path-
ways lead to the stimulation of TNF pro-
duction. I started looking at the signaling 
pathway downstream of LPS stimulation, 
and this is how I first encountered p38. 
I was specifi  cally looking for novel com-
ponents of that signaling pathway, and 
when I got a candidate protein, I went 
ahead and purifi  ed it, and it turned out to 
be p38.
It was a fortunate discovery for me, 
because shortly after discovering p38 I 
got promoted to assistant professor at 
Scripps. Basically everything has gone 
pretty smoothly for me since that time. I 
subsequently cloned p38, other p38 family 
members, and a few additional compo-
nents of the pathway. I should mention 
that other groups also cloned p38 shortly 
after us and contributed greatly to the study 
of p38.
Could you have built your career entirely 
on studying p38?
When I fi  rst found p38, all I knew about it 
was that it was a phosphorylated protein. 
After I purifi  ed and sequenced it, I real-
ized it was a kinase, and that it would 
probably have a lot of signaling functions 
Han studies the mechanisms of inflammation and immunity, and the 
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outside of this pathway as well. Of course, 
now we know that p38 is a MAPK, and 
that it has many different roles in cells. At 
fi  rst, though, I was mainly interested in its 
role in TNF production, so I spent a lot of 
time studying that aspect, but gradually I 
began to shift my focus away from that 
question, and I started to branch out into 
studying p38’s other roles. I don’t know if 
that was a good thing or not, but I kept 
coming up with new questions about the 
kinase. Even today, a large part of my lab 
is still working on p38.
Is p38’s role in inﬂ  ammation still a major 
focus of your lab?
Yes, this is still an important part of my 
lab’s research. People often ask me, 
what is my focus? Sometimes I have to 
think about it before I can answer them. 
Basically, we study the signaling path-
ways involved in the immunological re-
sponse to stress, and infl  ammation. But 
much of our work touches on subjects 
outside of infl  ammation, like cell metabo-
lism or death.
HOME AGAIN
What other aspects of p38 function are 
you working on now?
These days, we mostly work on animal 
models, looking for the in vivo roles of p38. 
There are four members of the p38 family, 
so we have a lot of work to do characteriz-
ing the functions of the different isoforms. 
Sometimes they have really quite different 
functions; for example, the p38- isoform 
seems to play a role in glucose homeostasis, 
and is connected with the insulin system. 
Other isoforms, like p38- and 
p38-, are important for cellular 
senescence, which is a major mech-
anism for protecting against tumor-
igenesis. We are studying p38- 
most closely, and we have found 
that it can modulate the activity of 
the tumor suppressor p53.
You mentioned that you are also 
working on cell death…
Actually, that is a very long story; 
we worked on that one for some 
time. We started working on it because of 
our interest in TNF. Certain cells, when 
treated with TNF, undergo necrotic cell 
death. The molecular basis of necrosis is 
poorly defi   ned right now, but the most 
practical defi  nition for our study is that it 
is a form of cell death that, unlike apopto-
sis, does not involve caspases. We wanted 
to see if we could fi  nd a key molecule that 
is important for necrosis.
We had been working on this problem 
for a while when I heard about a paper that 
another group had published, which 
claimed that TNF-treated NIH-3T3 cells 
didn’t undergo apoptotic cell death, be-
cause if you blocked caspases, the cells 
would still die. I thought this 
was interesting because, 
generally speaking and also 
in our hands, TNF treatment 
of NIH-3T3 cells causes 
apoptosis, and does involve 
caspases. So we got some of 
these necrotic NIH-3T3 
cells, and we compared their 
gene expression profile to 
our apoptotic NIH-
3T3 cell line. We found very few 
genes that were different, but the 
necrotic NIH-3T3 cells expressed a 
gene called Rip3. At that time, RNAi 
technology was just becoming avail-
able, so we knocked down Rip3 in 
the necrotic NIH-3T3 cells, and 
found that now they started to die by 
apoptosis. Later, we were able to 
show that the mechanism by which 
Rip3 causes cell death involves 
modulating metabolism and reac-
tive oxygen species production.
That sounds like a lot of different 
subjects to keep track of!
That is one of the reasons I moved back to 
China in 2007. Partly I just felt that it was 
time for a change of scenery, to keep 
things interesting. But I also wanted to 
have a big laboratory so that I could fol-
low up on everything we fi  nd, and con-
tinue to expand on it. I thought it would be 
easier to have a big laboratory in China—
although I still have a partial appointment 
at Scripps to fi  nish up the work I started 
while I was there.
The main difference between working in 
China and working at Scripps is that here, 
all the work in my lab is done by university 
students and graduate stu-
dents. On one hand, that is 
very nice because their sala-
ries are paid by the university, 
and the students here work 
very hard. That means I can 
have many people working 
on different projects, and I 
can get much more done 
with less money. On the other 
hand, there are not many 
postdocs in China; even though the research 
environment in China is now much stronger 
than it was, many Chinese students still go 
abroad for their postdocs. So, I basically 
have to train everyone up from the begin-
ning. That’s OK with me, though, because 
I think it’s fun working with students.
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Han training students in his lab.